LAVAL, Quebec--(BUSINESS WIRE)--Altasciences, a provider of top tier customer-tailored early phase clinical trial services, is pleased to announce that Chris Perkin, CEO at Altasciences, and his colleague, Dr. Brad Vince, CEO and Medical Director at Vince & Associates Clinical Research, an Altasciences company, have been named two of the 100 Most Inspiring People in the Life-Sciences Industry by PharmaVOICE magazine.
Every year, PharmaVOICE receives thousands of nominations from readers for the most influential corporate leaders, in their field. Candidates are selected based on their ability to inspire peers through their actions, as well as exhibiting strong leadership qualities, fearless and unique approaches to problems, and innovation in strategies, products and services.
“It’s an honor to be recognized by PharmaVOICE, especially in the same context as so many great industry leaders. I am grateful to all those who took the time to nominate me,” said Chris Perkin. When asked what motivates him, Chris replied “The satisfaction of working with others to continually problem solve and develop new or better services to meet the ever changing needs of our clients, and the industry. I am continuously impressed by our team of over 500 professionals from the medical, scientific and technical fields. Their ability to achieve so much by willingly working together and helping each other across departments and geographies is a credit to their dedication and commitment.”
“I am truly honored to be named as one of the 100 most inspiring people in the life science industry. This prestigious recognition by PharmaVOICE has only been possible because of the dedication of our research staff, the confidence of our clients and, most importantly, our study volunteers who choose to participate in clinical trials,” said Dr. Vince.
Altasciences, owned by Kilmer Capital Partners, owns Algorithme Pharma, Algorithme Pharma USA and Vince & Associates Clinical Research. All organizations operate with a common mission, to provide the best quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service. Altasciences, through its group of companies, provides comprehensive early stage clinical drug development services in Phase I/ IIa, including the necessary support services in this critical stage of drug development.
Leveraging the extensive expertise and capabilities within the group, the strategy is to maintain the core competencies and identity of each company and ensure that they benefit from the value of being part of a common larger organization focused on excellence in customer service, operating under the ALTASCIENCES banner.